ICON PLC
No SEC Form 4 filings for $ICLR in the last 30 days.
See all $ICLR insider activity →ICON plc (Nasdaq: ICLR) said its wholly owned subsidiary priced a US$2.15 billion senior unsecured notes offering. It includes US$500m 5.064% notes due 2029, US$1.0b 5.421% notes due 2031, and US$650m 5.995% notes due 2036. The offering is expected to close Aug. 13, 2026, subject to customary conditions.
ICON said it has a multi-year partnership with Anthropic to deploy Claude across its clinical trial operations, expanding AI capabilities for CRO workflows. The article focuses on operational and regulatory implications, including 21 CFR Part 11 audit trail attribution, site training and SOP readiness, IRB disclosure, and sponsor oversight under ICH E6(R3).
Greenskeeper Asset Management’s Q2 2026 scorecard says its fund rose 10.9% in the quarter, with YTD up 1.9%. In its investor letter, it cites ICON plc (NASDAQ:ICLR), a clinical research services firm, which gained 57% in Q2 after delayed year-end and Q1 results clarified prior accounting issues tied to revenue overstatements. ICON closed Aug 3, 2026 at $158.41.
Over the past 7 days, alphai's AI scored 4 news stories mentioning ICLR (ICON PLC). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent ICLR coverage spans technology, corporate actions and financial news.
The disclosed debt pricing is a capital-structure event that can affect funding costs and near-term credit/liquidity perceptions.
Likely modest near-term sentiment impact for ICON tied to operational readiness and Part 11 audit-trail validation risk, but no quantified financial effect is provided.
The article frames ICON plc’s rally as a resolution of previously disclosed accounting uncertainty from delayed/restated financials.
The refinancing and planned redemption should reduce near-term leverage and alter the company’s debt structure, but closing is not guaranteed.
Q2 results show modest revenue growth with stronger bookings and a reaffirmed full-year outlook, supporting a constructive near-term bias but with margin pressure signals.
alphai scores every news story that mentions ICLR with an AI model for sentiment and relevance, and aggregates insider trades from ICON PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
ICON plc (Nasdaq: ICLR) said its wholly owned subsidiary priced a US$2.15 billion senior unsecured notes offering. It includes US$500m 5.064% notes due 2029, US$1.0b 5.421% notes due 2031, and US$650m 5.995% notes due 2036. The offering is expected to close Aug. 13, 2026, subject to customary conditions.
2 min readICON said it has a multi-year partnership with Anthropic to deploy Claude across its clinical trial operations, expanding AI capabilities for CRO workflows. The article focuses on operational and regulatory implications, including 21 CFR Part 11 audit trail attribution, site training and SOP readiness, IRB disclosure, and sponsor oversight under ICH E6(R3).
7 min readGreenskeeper Asset Management’s Q2 2026 scorecard says its fund rose 10.9% in the quarter, with YTD up 1.9%. In its investor letter, it cites ICON plc (NASDAQ:ICLR), a clinical research services firm, which gained 57% in Q2 after delayed year-end and Q1 results clarified prior accounting issues tied to revenue overstatements. ICON closed Aug 3, 2026 at $158.41.
3 min readICON plc (NASDAQ: ICLR) said its wholly owned subsidiary plans a private offering of senior notes guaranteed by ICON. Net proceeds are intended to repay ICON’s bridge facility borrowings, repay existing term loans, and redeem its 5.809% senior secured notes due 2027. Collateral and subsidiary guarantees would be released after repayment, subject to closing.
3 min readICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.
3 min readHarris Oakmark’s Q2 2026 “Oakmark U.S. Concentrated Strategy” reported a 9.21% net return in the quarter. In the letter, it highlighted ICON Public Limited Company (NASDAQ:ICLR), citing two sets of results after an accounting review, bookings with a strong net book-to-bill and lower cancellations, margins meeting guidance, and plans to resume buybacks after next quarter’s earnings. ICLR closed at $180.24 on July 28, 2026.
4 min readICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.
3 min readICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.
2 min readICON plc (NASDAQ: ICLR) announced a multi-year collaboration with Anthropic to deploy Claude across ICON’s Orbis clinical trial platform. ICON says the work will build four production capabilities, including site planning, predictive enrolment risk detection, protocol optimization, and client ecosystem integration, with role-based rollout for developers, knowledge teams, and clinical/scientific users.
2 min readArtisan Mid Cap Value Fund’s Q1 2026 investor letter cited ICON Public Limited Company (NASDAQ:ICLR) as a major detractor. ICON shares fell nearly 49% in one day after it said it would delay financial results for an internal accounting review tied to revenue recognition. The fund reported ARTQX -4.93%, APDQX -4.90%, APHQX -4.97% versus the Russell Midcap Value Index up 3.68%.
4 min read
